Efficacy of 3 COVID-19 vaccine doses in lung transplant recipients: a multicentre cohort study.
Eur Respir J
; 2022 Oct 20.
Article
in English
| MEDLINE | ID: covidwho-2229298
ABSTRACT
QUESTION ADDRESSED BY THE STUDY Do three COVID-19 vaccine doses induce a serological response in lung transplant recipients? PATIENTS AND METHODS:
We retrospectively included 1071 adults (551 [52%] males) at nine transplant centres in France. Each had received three COVID-19 vaccine doses in 2021, after lung transplantation. An anti-spike protein IgG response, defined as a titre >264â BAU·mL-1 after (median, 3.0 [1.7-4.1] months) the third dose was the primary outcome, and adverse events were the secondary outcomes. Median age at the first vaccine dose was 54 [40-63] years and median time from transplantation to the first dose was 64 [30-110] months.RESULTS:
Median follow-up after the first dose was 8.3 [6.7-9.3] months. A vaccine response developed in 173 (16%) patients. Factors independently associated with a response were younger age at vaccination, longer time from transplantation to vaccination, and absence of corticosteroid or mycophenolate therapy. After vaccination, 51 (5%) patients (47 non-responders [47/898, 5%] and 4 [4/173, 2%] responders) experienced COVID-19, at a median of 6.6 [5.1-7.3] months after the third dose. No responders had severe COVID-19, compared to 15 non-responders, including six who died of the disease. ANSWER TO THE QUESTION Few lung transplant recipients achieved a serological response to three COVID-19 vaccine doses, indicating a need for other protective measures. Older age and use of mycophenolate or corticosteroids were associated with absence of a response. The low incidence of COVID-19 might reflect vaccine protection via cellular immunity and/or good adherence to shielding measures.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Cohort study
/
Observational study
/
Prognostic study
Topics:
Vaccines
Language:
English
Year:
2022
Document Type:
Article
Affiliation country:
13993003.00502-2022
Similar
MEDLINE
...
LILACS
LIS